Skip to content

Study · Not a test of the peptide alone · 1995

3 results

[Effectiveness of mexitil-depot in patients with chronic ventricular arrhythmia].

Golikov AP, Botolova EN, Rudnev DV

Klinicheskaia meditsina1 Jan 1995

PMID8691782 (opens in a new tab)PepBankPUB-08691782
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymogen (oglufanide).

  1. 01HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with asthma, timogen and myelopid medication, alone or combined, corrected immunodeficiency without a separate timogen estimate.

    In plain wordsIn patients with asthma, medication involving timogen and myelopid corrected immune deficiency, without a separate timogen result.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseImmunodeficiency correction
    Study

    n = 90

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Routine clinical and immunological tests show that the above medication corrects immunodeficiency and advances the efficacy of the basic treatment.
    1 context sentence
    Summary · context
    In addition to conventional treatment 90 asthmatics were given standard doses of timogen and myelopid alone and in combination.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  2. 02HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with asthma, timogen and myelopid medication, alone or combined, increased basic treatment efficacy without a separate timogen estimate.

    In plain wordsIn patients with asthma, medication involving timogen and myelopid increased basic treatment efficacy, without a separate timogen result.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseBasic treatment efficacy
    Study

    n = 90

    Outcome group
    Respiratory function · Respiratory

    Source sentences

    Summary
    Routine clinical and immunological tests show that the above medication corrects immunodeficiency and advances the efficacy of the basic treatment.
    1 context sentence
    Summary · context
    In addition to conventional treatment 90 asthmatics were given standard doses of timogen and myelopid alone and in combination.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  3. 03HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with asthma, combined timogen and myelopid showed the highest efficacy among the tested regimens.

    In plain wordsIn patients with asthma, combined timogen and myelopid showed greater efficacy than either drug alone.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseCombination efficacy
    Study

    n: not reported in source

    Comparator
    Timogen or myelopid alone
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In combination, timogen and myelopid displayed the highest efficacy.
    1 context sentence
    Summary · context
    In addition to conventional treatment 90 asthmatics were given standard doses of timogen and myelopid alone and in combination.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.